Maxivanil

Vancomycin Hydrochloride, the active ingredient in Maxivanil, is a glycopeptide antibiotic presented as an oral formulation for oral use. It treats Clostridioides difficile infection in patients requiring targeted antimicrobial therapy.

GNH USA supplies Maxivanil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maxivanil is a glycopeptide antibiotic used to manage infections caused by Clostridioides difficile. It acts within the gastrointestinal tract to eradicate the pathogen and restore normal gut flora.

- Clostridioides difficile infection: resolves diarrhea and colitis caused by toxin‑producing strains. - Recurrent C. difficile infection: helps prevent relapse after initial successful therapy. - Severe C. difficile‑associated colitis: contributes to clinical cure in complicated cases.

Adverse reactions may occur with oral vancomycin therapy. Most are mild and reversible, while some can be serious and require immediate medical attention.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional expulsion of stomach contents. - Abdominal pain: cramping or discomfort in the abdomen. - Diarrhea: increased loose stools unrelated to infection. - Metallic taste: altered taste sensation. - Loss of appetite: reduced desire to eat.

Serious or Rare Side Effects: - Nephrotoxicity: impaired kidney function, especially with prolonged use. - Ototoxicity: hearing loss or ringing in the ears. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Pseudomembranous colitis: worsening colonic inflammation. - Hematologic abnormalities: neutropenia or thrombocytopenia.

Oral vancomycin requires careful monitoring to minimize risks and ensure effective therapy.

- Assess renal function: evaluate kidney health before and during treatment. - Monitor hearing: watch for signs of ototoxicity, especially in prolonged courses. - Evaluate hypersensitivity: discontinue if allergic reactions develop. - Use only for confirmed C. difficile infection: avoid unnecessary exposure. - Avoid concurrent nephrotoxic drugs: limit combined use with aminoglycosides or NSAIDs. - Store at below 25°C: keep in the original pack, protect from moisture.

Vancomycin may interact with other medicines, altering efficacy or increasing toxicity.

Major Interactions (Avoid): - Aminoglycosides: combined use heightens risk of nephrotoxicity. - Loop diuretics: may increase ototoxic potential. - NSAIDs: can exacerbate renal impairment.

Moderate Interactions (Monitor Closely): - Oral antacids containing magnesium or aluminum: may reduce vancomycin absorption. - Warfarin: potential alteration of INR, requiring closer monitoring. - Metformin: renal function changes may affect drug clearance.